The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: Results from the estrogen in women with atherosclerosis study

Thrombosis Research

Volumn 98, Issue 1, 2000, Pages 19-27

  Høibraaten, Else ^a   Os, Ingrid ^b   Seljeflot, Ingebjørg ^b   Andersen, Trine O ^a   Hofstad, Ann Elin ^b   Sandset, Per Morten ^a  

^a Department of Haematology   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coagulation; Coronary artery disease; Estrogen; Fibrinolysis; Hormone replacement therapy

Indexed keywords

ANTITHROMBIN; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033998862     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00233-9     Document Type: Article

References (34)

1. Barrett-Connor E., Bush T.L. Estrogen and coronary heart disease in women. JAMA. 265:1991;1861-1867.
2. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 280:1998;605-613.
3. Bush T.L., Barrett-Connor E., Cowan L.D., Criqui M.H., Wallace R.B., Suchindran C.M. Cardiovascular mortality and noncontraceptive use of estrogen in women. Results from the Lipid Research Clinics Program Follow-up Study Circulation. 75:1987;1102-1109.
4. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 17:1997;3071-3078.
5. Falkeborn M., Persson I., Adami H.O., Bergstrom R., Eaker E., Lithell H., Mohsen R., Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 99:1992;821-828.
6. Sandset P.M., Larsen M.L., Abildgaard U., Lindahl A.K., Odegaard O.R. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI). Levels in the normal population and relation to cholesterol Blood Coagul Fibrinolysis. 2:1991;425-433.
7. Østergaard P.B., Beck T.C., Ørsted H., Svendsen A., Nordfang O., Sandset P.M., Hansen J.-B. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res. 87:1997;447-459.
8. Haaland A.K., Skjønsberg O.H., Vaeret A., Ruyter R., Godal H.C. A novel principle for assessment of stimulated fibrinolysis. Thromb Res. 62:1991;725-735.
9. Seljeflot I., Arnesen H., Eritsland J., Smith P. D-dimer test after standardized coagulation. Fibrinolysis. 7:1993;303-307.
10. 2.
11. Saleh A.A., Dorey L.G., Dombrowski M.P., Ginsburg K.A., Hirokawa S., Kowalczyk C. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol. 69:1993;1554-1557.
12. Caine Y.G., Bauer K.A., Barzegar S., ten Cate H., Sacks F.M., Walsh B.W. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 68(4):1992;392-395.
13. Kroon U.B., Silfverstolpe G., Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost. 71:1994;420-423.
14. Kroon U.B., Tengborn L., Rita H., Backstrom C. The effects of transdermal oestradiol and oral progestogens on haemostasis variables. Br J Obstet Gynaecol. 104:1997;32-37.
15. Shahar E., Folsom A.R., Salomaa V.V., Stinson V.L., McGovern P.G., Shimakawa T. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 93(11):1996;1970-1975.
16. Cushman M., Meilahn E.N., Psaty B.M., Kuller L.H., Dobs A.S., Tracy R.P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 19:1999;893-899.
17. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. 157:1987;1042-1048.
18. Lindberg U.B., Crona N., Stigendal L., Teger-Nilsson A.C., Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost. 61:1989;65-69.
19. Sporrong T., Mattsson L.A., Samsioe G., Stigendal L., Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol. 97:1990;939-944.
20. Bonduki C.E., Lourenco D.M., Baracat E., Haidar M., Noguti M.A., da Motta E.L., Lima G.R. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet Gynecol Scand. 77:1998;330-333.
21. van't Veer C., Mann K.G. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem. 72:1997;4367-4377.
22. van't Veer C., Golden N.J., Kalafatis M., Mann K.G. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem. 272:1997;7983-7994.
23. Sandset P.M. Tissue factor pathway inhibitor (TFPI) - An update. Haemostasis. 26:1996;154-165.
24. Sandset P.M., Warn-Cramer B.J., Rao L.V., Maki S.L., Rapaport S.I. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor. Evidence supporting a physiologic role for EPI as a natural anticoagulant Proc Natl Acad Sci USA. 88:1991;708-712.
25. Harris G.M., Stendt C.L., Vollenhoven B.J., Gan T.E., Tipping P.G. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol. 60:1999;175-180.
26. Scarabin P.Y., Plu-Bureau G., Bara L., Bonithon-Kopp C., Guize L., Samama M.M. Haemostatic variables and menopausal status. Influence of hormone replacement therapy Thromb Haemost. 70:1993;584-587.
27. Meilahn E.N., Kuller L.H., Matthews K.A., Kiss J.E. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol. 2:1992;445-455.
28. Scarabin P.Y., Vissac A.M., Kirzin J.M., Bourgeat P., Amiral J., Agher R., Amiral J., Agher R., Guize L. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol. 16:1996;1170-1176.
29. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K., Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 328:1993;1069-1075.
30. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:1995;199-208.
31. Gerbera O.C., Mittleman M.A., Sutherland P., Lipinska I., Matheney T., Xu P., Gebera O.C., Mittelman M.A., Sutherland P., Lipinska I., Matheney T., Xu P., Wetts F.K., Wilson P.W., Levy D., Muller J.E. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 91:1995;1952-1958.
32. Lip G.Y., Blann A.D., Jones A.F., Beevers D.G. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause. Implications for prevention of atherosclerosis Am Heart J. 134:1997;764-771.
33. Koh K.K., Mincemoyer R., Bui M.N., Csako G., Pucino F., Guetta V., Waclawiw M., Cannon R.O. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 336:1997;683-690.
34. Anonymous Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 346:1995;1582-1588.